About the Authors
- Hsien-Yi Chiu
-
Contributed equally to this work with: Hsien-Yi Chiu, Chi-Feng Hsieh
Affiliations Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan, Department of Dermatology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- Chi-Feng Hsieh
-
Contributed equally to this work with: Hsien-Yi Chiu, Chi-Feng Hsieh
Affiliation Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
- Yi-Ting Chiang
-
Affiliation Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
- Yi-Wen Tsai
-
Affiliation Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
- Weng-Foung Huang
-
Affiliation Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
- Cheng-Yuan Li
-
Affiliations Department of Dermatology, Taipei Veterans General Hospital, Taoyuan Branch, Taoyuan, Taiwan, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
- Ting-Shun Wang
-
Affiliations Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Division of Dermatology, National Taiwan University Hospital, Yun-Lin Branch, Dou-Liou, Taiwan
- Tsen-Fang Tsai
-
* E-mail: tftsai@yahoo.com
Affiliation Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
Competing Interests
Dr. Tsai has conducted clinical trials or received honoraria for serving as a consultant for Pfizer Pharmaceuticals, Serono International SA (now Merck Serono International), UniPharma/Biogen Idec, Galderma, Celgene, Novartis Pharmaceuticals and Janssen-Cilag Pharmaceutical, and has received speaking fees from AbbVie. Dr. Chiu has received speaking fees from AbbVie, Janssen-Cilag Pharmaceutical and Pfizer. Weng-Foung Huang has received research support from Novartis Pharmaceuticals. The other authors have no conflicts of interest to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: HYC CFH YTC YWT WFH CYL TSW TFT. Performed the experiments: HYC CFH YTC YWT WFH TFT. Analyzed the data: HYC CFH YTC YWT WFH CYL TSW TFT. Contributed reagents/materials/analysis tools: HYC CFH YTC YWT WFH TFT. Wrote the paper: HYC CFH YTC YWT WFH CYL TSW TFT.